Stay updated with breaking news from Ribosome Modulating Agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with...
WATERTOWN, Mass., Aug. 03, 2023 -- Eloxx Pharmaceuticals, Inc. , a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq...
Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) rocketed almost 100% yesterday
Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal…